Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Transfer Factor”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 127 records · Page 7Linked to original sources
PubMed1977

Transfer factor therapy in ataxia--telangiectasia.

The effects of weekly doses of transfer factor in four patients with ataxia--telangiectasia were investigated following a total course of 2 months therapy. Transfer factor administration showed no influence on the absolute lymphocyte counts, T-cell rosettes or antibody titres to EBV, but it caused conversion of skin-test reactivity and production of MIF to various antigens. There was a dissociation in blastic transformation response, the skin-test responses and MIF production. Serum interferon levels were low before, and 2, 6 and 24 hr after, therapy. Clinically no improvement in infections was observed following transfer factor therapy.

Antibodies, Viral↗
PubMed1994

Repeated measurements of transfer factor in rabbits: an animal model suitable for evaluation of short-term exposure.

Acute temporary changes in lung function may be of use as a biological exposure indicator. However, studies of humans occupationally exposed to complex airborne irritants are often expensive and time demanding. Therefore, an animal model could be a valuable complement. A rabbit model has been evaluated where transfer factor was measured twice during the same day, and with the rabbit awake and available for exposure, in between. Anaesthesia and intubation in 22 rabbits (2.6 [0.2] kg [Mean (SD)]) were immediately followed by two measurements of transfer factor and alveolar volume. Transfer factor was estimated by the single breath CO-technique used in humans. The samples were analysed for CO and He on a gas chromatograph. After one pair of measurements the rabbit was allowed to wake up and after 5 h the duplicate measurements were repeated. The mean values of transfer factor, alveolar volume and transfer constant were 0.50 (0.09) mmol min-1 kPa-1, 127 (8) ml and 3.9 (0.6) mmol min-1 kPa-1 l-1, respectively. The intraindividual coefficients of variation were 7.3%, 5.3% and 6.7%, respectively. Five hours later when the duplicate measurements were repeated, transfer factor, alveolar volume and transfer constant were unchanged still. The results suggest that relatively small changes in transfer factor may be detected without losing power, and thus that this model could be used as a biological exposure indicator.

Anesthesia↗
PubMedDate not supplied

The effects of transfer factor in adjuvant diseases in rats.

The improvement of the course of adjuvant arthritis by thymosin led us to use the transfer factor (biological active fraction of the homogenate of human tonsillar leukocytes) in this reported experiment. Transfer factor administered in the amount 200 micrograms (analogy of 10' leukocytes) 3 times a week was able to completely prevent the development of adjuvant arthritis. In the period of maximum development of adjuvant arthritis, symptoms were observed in control rats not treated with transfer factor (on day 21 after complete Freund adjuvants application) while in the transfer factor treated rats, swelling of the paws was not demonstrated and the mobility was the same as in that of the healthy ones. Signs of bone lesions were not present in these animals as well. Transfer factor has only a weak effect on interferon production in vivo.

Animals↗
PubMed1976

Inhibitory activity of medium-dialyzed transfer factor on lymphocyte blastogenesis.

Human transfer factor was prepared from normal donors with marked skin reactivity against common microbial antigens by dialysis of lymphocyte extracts versus tissue culture medium (TFmd). Several batches of TFmd were tested for their ability to specifically increase the DNA synthesis of unsensitized lymphocytes in vitro in the presence of the corresponding antigens (PPD, SKSD, Candida, Thistoplasmin). No transfer or immunologic reactivity by TFmd was observed. There was, however, a significant unspecific inhibition by TFmd of lymphocyte cultures stimulated by antigens, PHA or allogeneic cells.

Adult↗
PubMed2006

Transfer factors of 137Cs and 90Sr from soil to trees in arid regions.

Transfer factors of (137)Cs and (90)Sr from contaminated soil (Aridisol) to olive, apricot trees and grape vines were determined under irrigated field conditions for four successive years. The transfer factors (calculated as Bqkg(-1) dry plant material per Bqkg(-1) dry soil) of both radionuclides varied among tree parts and were highest in olive and apricot fruits. However, the values for (90)Sr were much higher than those for (137)Cs in all plant parts. The geometric mean of the transfer factors in olives, apricots and grapes were 0.007, 0.095 and 0.0023 for (137)Cs and 0.093, 0.13 and 0.08 for (90)Sr, respectively, and were negligible in olive oil for both radionuclides. The transfer factors of both radionuclides were similar to, or in the lower limits of, those obtained in other areas of the world. This could be attributed to differences in soil characteristics: higher pH, lower organic matter, high clay content, and higher exchangeable potassium and calcium.

Cesium Radioisotopes↗
PubMed1975

[The preparation and characterization of transfer factor (author's transl)].

A transfer factor (TF) was prepared and characterized from the leucocytes of Mantoux-positiv donors using a variety of techniques. The results allowed the following conclusions: Whilst extraction by dialysis and phenol (without precipitation) led to nearly the same positiv immunological activities, when assayed in the MEM-test, phenol extracts subjected to RNA-precipitation lost considerable activity. The residual activity was associated with the lower molecular fractions, and RNA itself has shown no activity. Residues after leucocyte dialysation have also shown considerable TF-activity when extracted by phenol. It was found that phenol extraction followed by gel filtration allowed recovery of considerable quantities of active TF, confined to several specific filtration fractions. Combination of active and inactive gel filtration fractions suggested that there existed an inhibitory factor within the extracted leucocyte preparations. This modified preparation and purification procedure may allow the preparation of TF for therapeutic purposes.

Chromatography, Gel↗
PubMed1983

A comparison of the effects of dialysed and non-dialysed transfer factor preparations on Haemonchus contortus infections in young lambs.

Significant reductions in worm burdens were achieved in lambs treated with dialysed transfer factor and challenged with 10,000 Haemonchus contortus larvae, when compared with challenged control animals. Non-dialysed transfer factor, from the same leucocyte pool, produced no protection, but was successful in reducing worm burdens when given after a primary infection of 1,000 H. contortus larvae with subsequent challenge of 10,000 larvae. While the results confirmed the previously reported inconsistencies of transfer factor activity, the histological abomasal changes in all the dialysed and non-dialysed transfer factor treated groups, irrespective of measurable effects on worm burdens, were consistent and corresponded to immediate type hypersensitivity responses. The similarity of these responses with self cure in haemonchosis and the possibility of genetic factors influencing the quantitative expression of protection to the effects of transfer factor treatments is discussed.

Abomasum↗
PubMed1988

The transfer factor and its subdivisions in patients with pulmonary emboli.

The carbon monoxide transfer factor and its subdivisions, the pulmonary membrane diffusing capacity and the pulmonary capillary volume were measured in fourteen subjects following submassive pulmonary emboli, as demonstrated by a ventilation-perfusion scan, and in fourteen matched controls. Transfer factor and alveolar volume were significantly lower in patients with pulmonary emboli (p less than 0.02). Patients were given six weeks anticoagulant therapy and the measurements repeated three months later. There was a significant increase in the transfer factor and the alveolar volume (p less than 0.01) and the membrane diffusing capacity (p less than 0.05). It has previously been assumed that the reduction in the transfer factor following a pulmonary embolus is due to a reduction in the pulmonary capillary volume. Results of this study however, suggest that it is more likely to be due to a loss of alveolar volume, at least in subjects with submassive emboli.

Adult↗
PubMed1997

[Immunomodulatory therapy of epilepsy with transfer factor].

Effect of immunotherapy with Transfer factor administered for a period of three months was studied in a group of ten epileptic patients, treated with carbamazepine or primidon previously and throughout the study. Out of eight patients, who finished the study we could notice significant reduction of epileptic discharges in eight patients. The results of this study prove that addition of immunomodulatory treatment to patients with intractable epilepsy could substantially improve the course of the disease in some patients. (Tab. 1, Fig. 5, Ref. 13.)

Adolescent↗
PubMed1996

Development of a general equation to determine the transfer factor feed-to-meat for radiocesium on the basis of the body mass of domestic animals.

Transfer factors from feed to meat (T f), taken from literature for monogastric animals and ruminants have been correlated to their corresponding animal body mass (mb). Taking all data into account, a close relationship between both transfer factor and body mass becomes evident, yielding a regression function of T f = 8.0 x mb(-0.91) (r = -0.97). For monogastric animals (including poultry), the corresponding relationships are T f = 5.8 x mb(-0.70) (r = -0.97), for ruminants T f = 1.9 x mb(-0.72) (r = -0.78). The equations offer the opportunity to estimate the transfer factor for individual animals more precisely taking individual body masses into account. They are of interest for animals, on which no or only poor data concerning radiocesium transfer factors are available. The determination of radiocesium transfer factors are reduced to a simple weighing process.

Animals↗
PubMed1996

Lessons from a pilot study of transfer factor in chronic fatigue syndrome.

Transfer Factor (TF) was used in a placebo controlled pilot study of 20 patients with chronic fatigue syndrome (CFS). Efficacy of the treatment was evaluated by clinical monitoring and testing for antibodies to Epstein-Barr virus (EBV) and human herpes virus-6 (HHV-6). Of the 20 patients in the placebo-controlled trial, improvement was observed in 12 patients, generally within 3-6 weeks of beginning treatment. Herpes virus serology seldom correlated with clinical response. This study provided experience with oral TF, useful in designing a larger placebo-controlled clinical trial.

Adolescent↗
PubMed1976

Nicotinamide: suppression of lymphocyte transformation with a component identified in human transfer factor.

The component in human transfer factor (TF) (Fraction IV, from exclusion chromatography on Sephadex G-25) responsible for suppression of antigen-induced lymphocyte transformation was previously identified as nicotinamide. Commercially available nicotinamide was subsequently shown to produce suppression of antigen-induced responses in vitro previously observed with TF Fraction IV. Nicotinamide was found to be nontoxic at the highest concentrations employed (10(-2)M) and suppressive over a relatively broad range (10(-5) to 10(-2)M. The suppression appeared to be related to the magnitude of antigen- or mitogen-induced transformation and was apparent even when nicotinamide was added as late as 48 hr after stimulant addition.

Antigens↗
PubMed1976

Human transfer factor: effects on lymphocyte transformation.

Transfer factor preparations from 57 different donors have been compared for effects on mitogen- and antigen-induced lymphocyte transformation. Nine of the preparations were mitogenic when added to cultured lymphocytes although the magnitude of this activity was relatively low. The majority of the preparations (48/57) did not affect PHA-induced lymphocyte transformation although augmentation (6 of 57) and suppression (3 of 57) was observed with some. In addition we observed that most of the preparations tested suppressed ConA stimulation and augmented the PWM response. When selected preparations were evaluated on antigen-responsive cells, there was a correlation between the magnitude of antigen responsiveness and the magnitude of TF augmentation of antigen-induced lymphocyte transformation (p less than 0.005). Cultures that were not responsive to antigen (KLH-negative or BUdR-treated) could not be stimulated by TF from immune donors and antigen. These data suggest that TF preparations contain either stimulatory or inhibitory components and that TF is not capable of activating naive lymphocytes to undergo transformation in response to antigen.

Antigens↗
PubMed1978

A double-blind trial of transfer factor vs placebo in multiple sclerosis patients.

A double-blind trial of the effect of transfer factor on multiple sclerosis patients was carried out. In a series of fifty-six multiple sclerosis patients treated with monthly injections of either transfer factor or placebo for 1 year, no beneficial effect of transfer factor was noted. In addition, none of the immunological and serological parameters studied (measles migration inhibition, measles HI titre or CSF immunoglobulin) changed as a result of transfer factor therapy. Histocompatibility typing and CSF IgG/TP ratios were correlated with the disease activity. Of interest was the finding that the presence of the DW2 antigen, when unassociated with HLA-B7 antigen, appeared to correlate with the mildest form of disease activity.

Adult↗
PubMed1995

Immunotherapy with transfer factor of recurrent herpes simplex type I.

This clinical trial of Transfer Factor, an immunomodulator, in the treatment of herpes simplex type I, proved this agent to be more effective as regards duration of acute phase recurrences as well as the frequency of the reappearance of relapses of this disease. The evaluation was made in 20 patients whose disease had been treated before with other therapeutic agents (including acyclovir) which permitted them to be their own controls for the comparative data obtained and submitted to statistical analysis of the two parameters mentioned, duration of the acute phase and frequency of relapses. Patients with compromised cellular immunity or with any additional disease were excluded from the study. Transfer factor, one unit, was administered subcutaneously daily for 3 to 4 days during the acute phase of the disease, and subsequently at 15-day intervals for the first 6 months; followed by a continuation of monthly injections until the termination of the study period. In six of the 20 patients there was a recurrence of the disease while receiving maintenance dosages of TF. These patients were again given the full initial dosage schedule and reinstated again with the maintenance dosage. In the initial eight patients, an immune status profile was obtained, and all results were found to be in the normal range. This was considered sufficient evidence that the criteria for the selection of patients excluded any with detectable variations in the profile of the immune status, and it was decided to eliminate this as a prerequisite for participating in the study. The results showed an important improvement in the response to transfer factor immune modulation therapy. A statistically significant reduction in the frequency of recurrences within a one month period, the Student t test gave a p = 0.0001 in TF treated patients. The average duration in days of the acute phase also showed an important difference in favor of the TF treatment. The U Mann-Whitney test gave a p = 0.0005. These results suggest that, at present, TF may be considered the therapeutic agent of choice in the treatment of herpes simplex type 1 disease.

Adolescent↗
PubMed1975

Use of transfer factor in patients with depressed cellular immunity and chronic infection.

Two patients with chronic mucocutaneous candidiasis and a defect in cellular immunity received a single injection of dialysable transfer factor from Candida-positive donors in an effort to reconstitute immunologic function. The transfer of cellular hypersensitivity was successful in one of the two patients and was monitored by skin tests and MIF production; however, the effect was temporary and did not change the clinical course of the patient's infection. The other patient did not respond eitherimmunologically or clinically to transfer factor at this time, although she did respond subsequently to repeated doses of transfer factor and amphotericin B therapy (Pabst and Swanson: Brit. med. J. 2:442, 1972). In another instance transfer factor from tuberculin-positive donors was used successfully to eradicate an infection in a patient with progressive primary tuberculosis and an acquired defect in cellular immunity. The patient had not responded clinically or bacteriologically after 7 1/2 months of antituberculous therapy, although the organism was shown to be sensitive in vitro to the drugs she was receiving. She received 6 doses of dialysable transfer factor over a 3-month period and during this time she responded clinically, bacteriologically and roentgenographically.

Adult↗
PubMed1982

Transfer of Salmonella resistance and delayed hypersensitivity with murine-derived transfer factor.

Protective host immunity and delayed hypersensitivity were transferred to nonimmune ICR and C3H/HeJ mice with transfer factor prepared from the splenic lymphocytes of ICR Swiss mice immune to Salmonella typhimurium. Only mice injected with the "immune" dialysate exhibited significant footpad swelling (P less than 0.01) to a spent medium antigen of S. typhimurium, but not Listeria monocytogenes. Host survival to a lethal Salmonella challenge infection was seen only in transfer factor-injected mice. Also, these challenged animals had fewer numbers of bacteria present in their spleens (P less than 0.01) than did challenged mice previously injected with either control dialysates or commercial endotoxin. Neither the Salmonella antigens nor endotoxin present in the sterile transfer factor preparation was responsible for the transfer of host protection and delayed hypersensitivity, since none of the control dialysates resulted in any positive responses when injected into either the ICR Swiss or endotoxin-resistant C3H/HeJ mice.

Animals↗
PubMed1979

A study of transfer factor for opportunistic infections in cancer patients.

Although supportive care during therapy of patients with malignancies has improved, infection remains the major cause of death in these patients. The problem of "opportunistic" infections is becoming more apparent as better antibiotics are found. The control of these infections depends in part on mechanisms of cell-mediated immunity. It has been demonstrated that delayed-type hypersensitivity can be transferred from one person to another. Therefore, we used transfer factor in the treatment of 15 patients, most with leukemia, who had fungal, viral, or mycobacterial infections that were not responding to conventional therapy. Seven of ten evaluable patients had therapeutic control of their infections while receiving transfer factor. Transfer factor appears to have contributed to these clinical improvements and is a modality of treatment that deserves further investigation.

Adolescent↗